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were, furthermore, more sensitive to the presence of side effects than EQ-5D. 
 CONCLUSIONS: TooL is a novel system for measuring health utilities in patients 
with schizophrenia, schizoaffective disorder or bipolar depression that incorporates 
the patient perspective of side effects of antipsychotic treatment. Adverse effects from 
antipsychotic treatment impact the quality-of-life and should be taken into account in 
economic evaluations of treatments with different side effect proﬁles. TooL facilitates 
cost-utility analyses that reﬂect this important aspect of treatment choice and 
outcome.
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OBJECTIVES: To investigate the relationship of severity levels of anxiety identiﬁed 
by the GAD-7 scale and the degree of disability as assessed by other standard widely 
used questionnaires. METHODS: A random sample of 212 subjects was recruited in 
Mental Health and Primary Care centres; 50% diagnosed of Generalized Anxiety Dis-
order (GAD) by DSM-IV criteria, and the other 50% were concurrent matched con-
trols. In addition to the GAD-7, the following scales were also administered: Hamilton 
Anxiety scale (HAM-A), Hospital Anxiety and Depression Scale (HADS), and World 
Health Organization Disability Scale (WHO-DAS). The number of visits to primary 
care and specialized services were also measured. Correlations between scale scores 
were computed and also agreement between instrument-speciﬁc disability and severity 
levels. RESULTS: Strong and signiﬁcant (p  0.001) correlations were found between 
GAD-7 scores and other questionnaires: HAM-A (r  0.852), HADS-A (r  0.903), 
WHO-DAS (r  0.704). Although GAD-7 scores correlated with all WHO-DAS dimen-
sions, higher correlations were observed with Social Participation (r  0.741), Com-
prehension and Communication (r  0.679), and Labour (0.638) dimensions. Moderate 
but signiﬁcant correlations were also found between GAD-7 scores and the number 
of visits to Primary Care (r  0.393) and Specialized Services (r  0.373). HAM-A 
severity groups presented signiﬁcant differences in GAD-7 mean scores (F  205.3; 
df1  3; df2  208; p  0.001), and HAM severity groups also differed (F  175.3; 
df1  3; df2  208; p  0.001); in both cases all severity levels differed. CONCLU-
SIONS: The GAD-7 scale has shown to highly correlate not only with speciﬁc anxiety 
measures but also with disability measures. Not all WHO-DAS disability dimensions 
seem to be equally affected by GAD levels, and it has been shown that more 
severe GAD levels tend to demand more health attention. As the GAD-7 is self-admin-
istered and it is no time consuming, this instrument could be a good choice in primary 
care settings to explore the level of patient’s disability in subjects with GAD.
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BACKGROUND: IQWiG, the German health technology assessment agency, is 
required to focus on patient-relevant endpoints as part of their cost-beneﬁt analysis. 
Several patient preference studies conducted in Germany have identiﬁed “clear think-
ing” as a patient-relevant endpoint, but the measurement of this construct is limited 
by the absence of a conceptualization of clear thinking that is grounded in the patient 
experience. OBJECTIVES: To develop a conceptual model of clear thinking grounded 
in the experience of patients diagnosed with schizophrenia, aiding the creation of clear 
thinking scale. METHODS: A trained psychologist elicited deﬁnitions and examples 
of clear thinking from 25 German patients diagnosed with schizophrenia during open-
end, semi-structured interviews. Theory building was aided by literature review, 
including a review of existing scales of cognition, and an additional 15 depth inter-
views with patients and clinicians. Data was analyzed using a grounded theory 
approach, leading to multi-dimensional conceptualization of clear thinking. RESULTS: 
Clear thinking can be conceptualized by four themes: a) staying organized (including 
daily activities, making decisions and having organized thoughts); b) making sense of 
the world (identifying reality, verbal comprehension and visual comprehension); c) 
feeling clear headed (confusion, slowness and pacing); and d) expressing thoughts and 
feelings (feelings, communication and fullness of life). CONCLUSIONS: This concep-
tual model provides researchers and clinicians with a framework to consider clear 
thinking as deﬁned by patients diagnosed with schizophrenia. It will also provide the 
cornerstone for the development of a clear thinking scale to measure this patient-
 relevant endpoint and subsequently assess the validity of our conceptualization.
PMH61
PATIENTS PREFERENCES IN ADULTS WITH ADHD—A DISCRETE 
CHOICE EXPERIMENT
Mühlbacher AC1, Slawik L2, Kasper J3, Nübling M4
1Hochschule Neubrandenburg, Neubrandenburg, Germany, 2Janssen Cilag GmbH, Neuss, 
Germany, 3GEB: Gesellschaft für Empirische Beratung mbH—Empirical Consulting -, Freiburg, 
Germany, 4Gesellschaft für empirische Beratung mbH, D- 79211 Denzlingen, Germany
OBJECTIVES: For the majority of those concerned, ADHD is a lifelong chronic 
disease with prevalent underachievement in work life and impairments in social 
functioning. While clinical evidence on efﬁcacy and tolerability of treatment options 
for ADHD in adulthood is increasing, preferences of adults with ADHD have not yet 
been explored. Understanding their preferences contributes to present discussions in 
the health care sector on patients’ needs and shared decision-making. METHODS: An 
extended qualitative study (literature review, in-depth interviews and patient focus 
groups) was conducted in order to collect all relevant factors and success criteria for 
adults with ADHD (content validity). In the subsequent quantitative study, preferences 
for an ADHD treatment were investigated by using direct measurement (rating 23 
aspects on a ﬁve point Likert-scale) as well as a Discrete-Choice-Experiment (DCE) 
with 8 pairs of treatment options described by 6 dichotomous parameters. RESULTS: 
14 in-depth interviews and ﬁve focus groups with 4–12 adult participants each (n  
35) were conducted. 329 persons (18- 65 years, 63%female) ﬁlled the questionnaire 
of the quantitative study (89% online, 11% paper&pencil). In the direct assessment, 
“long-term positive effects (e.g. behaviour changes)”, “improved ability to concen-
trate”, “allows “normal” daily living” and “improves emotional stability” reached 
the highest values (means around 90). In the DCE (random effects logit model) “social 
abilities (profession, friendship possible)” had the highest impact on choices (coefﬁ-
cient 2.12) followed by “long-term behaviour changes” (1.75), “fast symptom relief” 
(1.10), “no impact on positive ADHD traits” (1.04), and “emotional stability (no 
mood swings)” (0.81). These factors were highly signiﬁcant (p  0.001) while “neces-
sity of medical treatment” had no signiﬁcant inﬂuence. CONCLUSIONS: The pre-
sented study systematically explored patient preferences and hereby contributes to a 
better understanding of the medical needs of adults diagnosed with ADHD. The 
achievement of social abilities and long lasting behavioural effects attributed greatest 
beneﬁt to the respondents.
PMH62
THE SPANISH VERSION OF THE TOOL QUESTIONNAIRE: VALIDATION 
OF A SPECIFIC MEASURE TO EVALUATE HEALTH RELATED QUALITY 
OF LIFE (HRQOL) IN PATIENTS WITH SCHIZOPHRENIA AND BIPOLAR 
DISORDER
Maurino J1, Cordero L2, Montejo AL3, Correas Lauffer J4, Cuervo J5, Rebollo P5, Diez T2, 
Hernandez R2
1AstraZeneca, Madrid, Spain, 2AstraZeneca Farmacéutica Spain S.A, Madrid, Spain, 3Hospital 
Universitario de Salamanca, Salamanca, Spain, 4Hospital del Henares, Coslada, Spain, 5BAP 
Health Outcomes Research, Oviedo, Spain
OBJECTIVES: To develop a cross-cultural adaptation from Swedish into Spanish of 
the TooL questionnaire—a previously validated instrument to assess side effects’ 
impact on HRQoL in patients with schizophrenia and bipolar disorder. METHODS: 
An epidemiological multicentre, cross-sectional study was carried out to analyze the 
psychometric properties of the Spanish TooL. It comprises 8 attributes and 4 levels 
per domain (Likert scale: 1-minimun impact; 4-maximun impact): worry-upset, func-
tion capabilities, fatigue-weakness, weight gain, stiffness-tremor, physical restlessness, 
sexual dysfunction, and dizziness-nausea. Patients completed both generic and speciﬁc 
measures of HRQoL and severity (EQ-5D and SF6D –unweighted- and the Clinical 
Global Impression -CGI-SI-, UKU side effects rating scale, Positive and Negative Syn-
drome scale, Young Mania Rating Scale, Montgomery Adsberg Depression Rating 
Scale). Reliability (Cronbach’s A and intraclass correlation coefﬁcient –ICC-), con-
struct validity (factorial analysis –FA- and item-total correlations -ITC), convergent 
validity (Spearman’s rank correlations between measures –rs-) and criterion validity 
(Mann-Whitney U differences between mild vs moderate-severe patients according to 
CGI-SI) were evaluated. RESULTS: A total of 242 patients were included (121 with 
schizophrenia and 121 with bipolar disorder). Internal consistency and ICC were 
adequate (Cronbach’s A  0.757 & ICC  0.90). FA and ITC showed that one-
 dimensional structure could be assumed (1 eigenvalue 1 and 40% of variance 
explained). Correlations (rs) between the Spanish TooL and both generic and speciﬁc 
measures were moderate-high. Differences in the Spanish TooL scores between mild 
vs moderate-severe patients were highlighted. CONCLUSIONS: The Swedish TooL 
questionaire was culturally adapted and validated into Spanish. Further investigation 
is needed to test the sensitivity of the Spanish TooL questionnaire.
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OBJECTIVES: To estimate and assess the psychometric properties of a Multi-Attribute 
Utility Function for the Spanish version of the TOOL questionnaire (TOOL MAUF). 
TOOL is a recently developed 8-item (4-level) instrument measuring antipsychotics 
side effects´ impact on health status. METHODS: Balanced data on 242 patients 
diagnosed with schizophrenic or bipolar disorders were gathered. In addition to 
demographic and clinical variables, and the usual generic HRQoL questionnaires, 
EQ5D and SF6D, instruments considered included the Spanish versions of the Positive 
and Negative Syndrome Scale (PANSS), Young Mania Rating Scale (YMRS), Mont-
gomery-Asberg Depression Rating Scale (MADRS), UKU side effect rating scale, and 
TOOL questionnaire. TOOL MAUF parameters estimation involved a number of VAS 
and TTO ratings of different health states deﬁned from TOOL items. Such ratings 
proved hard to be performed by patients. After checking for inconsistencies in patient 
responses (missing data, out-of-range responses, and rating reversals), the original 
